RESUMEN
Role of propranolol and cyproheptadine in the prophylaxis of migraine was studied in a controlled double blind trial. Two hundred fifty-nine patients were divided into four groups. Each group was either given a placebo, cyproheptadine, propranolol or a combination of the latter two drugs. The patients were followed for a period of three months. Significant relief in frequency, duration and severity from migranous attacks was seen in all drug treated groups over placebo. Significant correlation in response was seen in frequency, duration and severity in all the groups which received drugs. Statistically more significant relief was seen in cyproheptadine and propranolol treated group as compared to individual drug treated groups. In cyproheptadine and propranolol treated groups, the dropout rate was lower and associated symptoms were better relieved than in other groups. The study shows efficacy of combination of cyproheptadine and propranolol in migraine prophylaxis.
Asunto(s)
Adolescente , Adulto , Ciproheptadina/administración & dosificación , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastornos Migrañosos/tratamiento farmacológico , Propranolol/administración & dosificación , Antagonistas de la Serotonina/administración & dosificación , Vasodilatadores/administración & dosificaciónRESUMEN
BACKGROUND: Kamalahar is an indigenous preparation reported to be beneficial in acute viral hepatitis. AIMS: To evaluate the efficacy of Kamalahain acute viral hepatitis in a double-blind, placebo-controlled study. METHODS: Fifty two patients with acute viral hepatitis were randomized to receive either Kamalahar 500 mg or a matched placebo three times a day for 15 days. Forty four patients (Kamalahar 20; placebo 24) completed the trial. RESULTS: Improvement in clinical signs was more marked with Kamalahar compared to placebo. The fall in serum bilirubin (p < 0.001), SGPT (p < 0.001) and serum alkaline phosphatase (p < 0.005) at day 15 was significantly greater with the drug. No significant side effects were observed. CONCLUSION: Kamalahar offers therapeutic promise in acute viral hepatitis.
Asunto(s)
Enfermedad Aguda , Adolescente , Adulto , Método Doble Ciego , Femenino , Hepatitis Viral Humana/tratamiento farmacológico , Humanos , Masculino , Medicina Ayurvédica , Persona de Mediana Edad , Extractos Vegetales/uso terapéuticoRESUMEN
A study was undertaken to assess the prescribing trends in inpatients of the Internal Medicine Department of Government General Hospital which is attached to Guntur Medical College, Guntur. Prescriptions for 250 patients were audited under various heads like details of drugs used, generic versus trade name prescribing, dosage, dosage form, dose interval, drug of choice and duration of treatment. Among 250 prescriptions audited, 7 percent used generic names, 22 percent trade names, and 71 percent combinations of both generic and trade names. Dosages and dosage intervals were appropriate. In 75 percent of the audited cases, the duration of treatment was appropriate; 25 percent did not specify the duration. The choice of drugs was proper in 84 percent and inappropriate in 16 percent of cases. Certain deficiencies in the prescribing trends are analysed.